BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA : THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM) 2009-01 PROTOCOL

被引：0
|
作者：
Rodon, P. [1 ]
Hulin, C. [2 ]
Pegourie, B. [2 ]
Tiab, M. [3 ]
Anglaret, B. [3 ]
Benboubker, L. [2 ]
Jardel, H. [3 ]
Decaux, O. [2 ]
Kolb, B. [2 ]
Roussel, M. [2 ]
Garderet, L. [4 ]
Leleu, X. [5 ]
Royer, B. [2 ]
Banos, A. [3 ]
Benramdane, R. [3 ]
Cony-Makhoul, P. [3 ]
Dib, M. [2 ]
Fontan, J. [2 ]
Stoppa, A. [6 ]
Traulle, C. [7 ]
Vilque, J. [8 ]
Moreau, P. [2 ]
Mathiot, C. [9 ]
Avet-Loiseau, H. [2 ]
机构：
[1] Ctr Hosp, Blois, France
[2] CHU, Nancy, France
[3] CH, La Roche Sur Yon, France
[4] Hop St Antoine, Paris, France
[5] CHRU, Lille, France
[6] Inst Paoli Calmettes, Marseille, France
[7] Hop Sud, Lyon, France
[8] Ctr Francois Baclesse, Caen, France
[9] Inst Curie, Paris, France
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0835
引用
收藏
页码：342 / 342
页数：1
相关论文
共 50 条
  • [41] Bortezomib in combination with bendamustine and prednisone in the treatment of patients with refractory/relapsed multiple myeloma
    Poenisch, W.
    Bourgeois, M.
    Wang, S. Y.
    Heyn, S.
    Jaekel, N.
    Al Ali, H.
    Niederwieser, D.
    ONKOLOGIE, 2008, 31 : 136 - 136
  • [42] Growth Differentiation Factor 15 Plasma Level in patients with Multiple Myeloma: A Study of Intergroupe Francophone Du Myelome.
    Corre, Jill
    Roussel, Murielle
    Huynh, Anne
    Gadelorge, Melanie
    Labat, Elodie
    Laharrague, Patrick
    Moreau, Philippe
    Facon, Thierry
    Avet-Loiseau, Herve
    Fournie, Jean-Jacques
    Attal, Michel
    Bourin, Philippe
    BLOOD, 2008, 112 (11) : 934 - 934
  • [43] Bendamustine-Bortezomib-Desametasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma : A REAL-Life Experience
    Cerchione, Claudio
    Catalano, Lucio
    Pareto, Anna Emanuele
    Basile, Santina
    Marano, Luana
    Peluso, Ilaria
    Simeone, Luigia
    Vitagliano, Orsola
    Nappi, Davide
    Palmieri, Salvatore
    Rocco, Stefano
    Ferrara, Felicetto
    Pane, Fabrizio
    BLOOD, 2016, 128 (22)
  • [44] Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myelome (IFM)
    Touzeau, Cyrille
    Leleu, Xavier P.
    Mariette, Clara
    Manier, Salomon
    Brechignac, Sabine
    Vincent, Laure
    Hebraud, Benjamin
    Decaux, Olivier
    Schulmann, Samantha
    Lenoir, Caroline
    Godmer, Pascal
    Farge, Agathe
    Saint Paul, Laure Peyro
    Parienti, Jean-Jacques
    Macro, Margaret
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] BENDAMUSTINE-BORTEZOMIB-DESAMETASONE (BVD) IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REAL-LIFE EXPERIENCE
    Cerchione, C.
    Catalano, L.
    Pareto, A. E.
    Basile, S.
    Marano, L.
    Peluso, I.
    Simeone, L.
    Vitagliano, O.
    Palmieri, S.
    Ferrara, F.
    Pane, F.
    HAEMATOLOGICA, 2016, 101 : 792 - 792
  • [46] Bendamustine-Bortezomib-Dexametasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma: A Real-Life Experience
    Cerchione, Claudio
    Catalano, Lucio
    Pareto, Anna Emanuele
    Basile, Santina
    Marano, Luana
    Peluso, Ilaria
    Simeone, Luigia
    Vitagliano, Orsola
    Palmieri, Salvatore
    Rocco, Stefano
    Romano, Alessandra
    Ferrara, Felicetto
    Pane, Fabrizio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S343 - S343
  • [47] Ixazomib and Daratumumab without Dexamethasone (I-Dara) in Elderly Frail RRMM Patients. a Multicenter Phase 2 Study (IFM 2018-02) of the Intergroupe Francophone Du Myelome (IFM)
    Macro, Magaret
    Touzeau, Cyrille
    Mariette, Clara
    Manier, Salomon
    Brechignac, Sabine
    Vincent, Laure
    Hebraud, Benjamin
    Decaux, Olivier
    Schulmann, Samantha
    Lenoir, Caroline Bureau
    Godmer, Pascal
    Parienti, Jean-Jacques
    Leleu, Xavier
    BLOOD, 2021, 138
  • [48] Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma
    Moreau, Philippe
    Chanan-Khan, Asher A.
    Roberts, Andrew W.
    Agarwal, Amit B.
    Facon, Thierry
    Kumar, Shaji
    Touzeau, Cyrille
    Cordero, Jaclyn
    Ross, Jeremy
    Munasinghe, Wijith
    Jia, Jia
    Salem, Ahmed H.
    Leverson, Joel
    Maciag, Paulo
    Verdugo, Maria
    Harrison, Simon J.
    BLOOD, 2016, 128 (22)
  • [49] Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myelome
    Roussel, Murielle
    Lauwers-Cances, Valerie
    Robillard, Nelly
    Hulin, Cyrille
    Leleu, Xavier
    Benboubker, Lotfi
    Marit, Gerald
    Moreau, Philippe
    Pegourie, Brigitte
    Caillot, Denis
    Fruchart, Christophe
    Stoppa, Anne-Marie
    Gentil, Catherine
    Wuilleme, Soraya
    Huynh, Anne
    Hebraud, Benjamin
    Corre, Jill
    Chretien, Marie-Lorraine
    Facon, Thierry
    Avet-Loiseau, Herve
    Attal, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) : 2712 - +
  • [50] Escalation treatment algorithm with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma: A singel centre experience.
    Fenk, Roland
    Michael, Mark
    Zohren, Fabian
    Graef, Thorsten
    Czibere, Arkosch
    Balleisen, Sebastian
    Neumann, Frank
    Rohr, Ulrich-Peter
    Steidl, Ulrich
    Haas, Rainer
    Kobbe, Guido
    BLOOD, 2006, 108 (11) : 1010A - 1010A
12345